Sign In
Buy BHC
$4.95
-0.0600 (-1.20%)
At Close: Jun 03, 2026
Bausch Health (BHC) Surpasses Q4 Earnings and Revenue Estimates
09:26am, Thursday, 22'nd Feb 2024
Bausch Health (BHC) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $1.02 per share a year ago.
Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?
01:11pm, Wednesday, 21'st Feb 2024
Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Biotech/Drug Stocks Q4 Earnings Due Feb 22: MRNA, BHC, NTLA, BMRN & More
10:16am, Wednesday, 21'st Feb 2024
Let us take a look at what's in store for biotech/drug stocks MRNA, BHC, NTLA, BMRN and ITCI, which are scheduled to report on Feb 22.
Insights Into Bausch (BHC) Q4: Wall Street Projections for Key Metrics
10:21am, Monday, 19'th Feb 2024
Evaluate the expected performance of Bausch (BHC) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f
Analysts Estimate Bausch Health (BHC) to Report a Decline in Earnings: What to Look Out for
11:06am, Thursday, 15'th Feb 2024
Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bausch (BHC) Upgraded to Strong Buy: What Does It Mean for the Stock?
01:01pm, Wednesday, 07'th Feb 2024
Bausch (BHC) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Best Value Stocks to Buy for February 7th
04:06am, Wednesday, 07'th Feb 2024
MITSY, JSAIY and BHC made it to the Zacks Rank #1 (Strong Buy) value stocks list on February 7, 2023.
Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2023 Financial Results on February 21
12:00pm, Monday, 05'th Feb 2024
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its fourth-quarte
Bausch Health to Announce Fourth-Quarter and Full-Year 2023 Results on Feb. 22
08:00am, Thursday, 01'st Feb 2024
LAVAL, QC / ACCESSWIRE / February 1, 2024 / Bausch Health Companies Inc. (NYSE/TSX:BHC) will release fourth-quarter and full-year 2023 financial results on Thursday, Feb. 22, 2024. Bausch Health will
Bausch + Lomb CEO: 2024 is the biggest year of new product launches the company has ever seen
11:58am, Tuesday, 09'th Jan 2024
Bausch + Lomb CEO Brent Saunders joins 'Money Movers' to discuss how the company will make eye care as exciting as Botox, what an investment year entails, and if supply chain issues are still a proble
Bausch Health (BHC) Ulcerative Colitis Drug Meets Primary Goal
12:02pm, Friday, 22'nd Dec 2023
Bausch's (BHC) amiselimod achieves the primary and key secondary endpoints, including clinical and endoscopic measures, in the double-blind period of a phase II study.
Are Medical Stocks Lagging Bausch Health (BHC) This Year?
11:17am, Monday, 18'th Dec 2023
Here is how Bausch Health (BHC) and Connect Biopharma Holdings Limited Sponsored ADR (CNTB) have performed compared to their sector so far this year.
3 cheap 'stock'-ing stuffers Wall Street is bullish on
10:41am, Thursday, 07'th Dec 2023
Known for historically being the strongest month of the year for U.S. stocks, the Dow and S&P 500 both gained nearly 9% last month. The Nasdaq, almost 11%.
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
11:17am, Thursday, 30'th Nov 2023
Here is how Bausch Health (BHC) and Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have performed compared to their sector so far this year.
Bausch (BHC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:18am, Monday, 13'th Nov 2023
Bausch (BHC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend
